News Release

Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor Briefing

-- Long-term development pipeline has the potential to deliver greater than $1 billion in annual net sales at peak --
-- Pipeline expected to contribute >20% of total growth long term --
-- Four product launches expected over next three years --

STAINES-UPON-THAMES, United Kingdom, Oct. 4, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, is holding its investor briefing today in New York City with presentations by Mallinckrodt executives Mark Trudeau, President and Chief Executive Officer; Ron Lloyd, Executive Vice President and President, Hospital Therapies; Hugh O'Neill, Executive Vice President and President, Autoimmune and Rare Diseases; and Steve Romano, M.D., Executive Vice President and Chief Scientific Officer.

The event will highlight how Mallinckrodt's ongoing portfolio transformation has enhanced financial strength and broadened future opportunities, providing long-term value for patients and shareholders.

At the briefing, members of the company's management team and medical experts, both internal and external, will share insights on a number of topics, including:

  • Development pipeline highlights:
    • Updates on the company's broad spectrum of near- and longer-term developmental programs for inline and investigational assets, including clinical and health economic data
    • Aggregate net sales expectations for near-term development programs, the sum of which is expected to exceed $675 million at peak, with total pipeline expected to exceed net sales of $1 billion at peak
    • Pipeline expected to contribute >20% of total growth long term
    • Four product launches expected over next three years
  • Scientific poster presentations on key development products; and
  • Product demonstrations of the INOMAX and Therakos platforms.

Poster presentations for the Investor Briefing can be found at the company's Investor Relations website at The event general session presentations will be posted throughout the day.

Those unable to attend the briefing in person can view a live webcast of the presentations and Q&A session at Mallinckrodt's Investor Relations website, linked here, beginning at 11:45 a.m. Eastern Time, with the general session expected to conclude at approximately 5:15 p.m. The poster session will not be available via webcast.


Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Cautionary Statements Related to Forward-Looking Statements
Statements in this document that are not strictly historical, including statements regarding future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting Mallinckrodt's businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.

There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Mallinckrodt operates; the commercial success of Mallinckrodt's products; Mallinckrodt's ability to realize anticipated growth, synergies and cost savings from transactions; conditions that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets for possible impairment; changes in laws and regulations; Mallinckrodt's ability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings; Mallinckrodt's ability to successfully develop or commercialize new products; Mallinckrodt's ability to protect intellectual property rights; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; the reimbursement practices of a small number of public or private insurers; pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; limited clinical trial data for H.P. Acthar® Gel; complex reporting and payment obligations under healthcare rebate programs; Mallinckrodt's ability to navigate price fluctuations; future changes to U.S. and foreign tax laws; Mallinckrodt's ability to achieve expected benefits from restructuring activities; complex manufacturing processes; competition; product liability losses and other litigation liability; ongoing governmental investigations; material health, safety and environmental liabilities; retention of key personnel; conducting business internationally; the effectiveness of information technology infrastructure; and cybersecurity and data leakage risks.

These and other factors are identified and described in more detail in the "Risk Factors" sections of Mallinckrodt's Annual Report on Form 10-K for the fiscal year ended September 30, 2016. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Investor Relations   
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy & IRO

Daniel J. Speciale, CPA
Director, Investor Relations

Rhonda Sciarra
Senior Communications Manager

Meredith Fischer
Chief Public Affairs Officer


View original content with multimedia:

SOURCE Mallinckrodt plc